1
|
Alexander GC, Hwang PTJ, Chen J, Kim J, Brott BC, Yoon YS, Jun HW. Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions. ACS Biomater Sci Eng 2017; 4:107-115. [PMID: 31538110 DOI: 10.1021/acsbiomaterials.7b00676] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events including restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.
Collapse
Affiliation(s)
- G C Alexander
- Department of Biomedical Engineering, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| | - P T J Hwang
- Department of Biomedical Engineering, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| | - J Chen
- Department of Biomedical Engineering, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| | - J Kim
- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| | - B C Brott
- School of Medicine, Division of Cardiology, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| | - Y S Yoon
- School of Medicine, Division of Cardiology, Emory University, Atlanta, Georgia 30322, United States.,Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea
| | - H-W Jun
- Department of Biomedical Engineering, University of Alabama at Birmingham, 806 Shelby Building, 1825 University Boulevard, Birmingham, Alabama 35294, United States
| |
Collapse
|
2
|
Ford NF. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. J Clin Pharmacol 2016; 56:1474-1483. [DOI: 10.1002/jcph.769] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 05/06/2016] [Accepted: 05/06/2016] [Indexed: 12/12/2022]
Affiliation(s)
- Neville F. Ford
- Woodfield Clinical Consulting LLC; Green Valley AZ USA
- Rutgers-RWJ Medical School; New Brunswick NJ USA
| |
Collapse
|
3
|
Bundhoo S, Sagan E, James PE, Anderson RA. Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention. Thromb Haemost 2013; 111:373-4. [PMID: 24154807 DOI: 10.1160/th13-05-0394] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 09/12/2013] [Indexed: 11/05/2022]
Affiliation(s)
| | | | | | - Richard A Anderson
- Richard A. Anderson, Cardiovascular Biology and Metabolism, The Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, CF14 4XN, UK, Tel.: +44 2920743786, Fax: +44 2920744473, E-mail:
| |
Collapse
|